SubHero Banner

Pomalyst® (pomalidomide), Revlimid® (lenalidomide), Thalomid® (thalidomide) – New warning

November 29, 2017 – The FDA approved an update to the Warnings and Precautions section of the Pomalyst (pomalidomide), Revlimid (lenalidomide), and Thalomid (thalidomide) drug labels regarding increased mortality in patients with multiple myeloma (MM) when Keytruda® (pembrolizumab) is added to a thalidomide analogue and dexamethasone.

Download PDF